239 related articles for article (PubMed ID: 29458967)
1. Improving Cancer Immunotherapies through Empirical Neoantigen Selection.
Nogueira C; Kaufmann JK; Lam H; Flechtner JB
Trends Cancer; 2018 Feb; 4(2):97-100. PubMed ID: 29458967
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy targeting neoantigens.
Lu YC; Robbins PF
Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
[TBL] [Abstract][Full Text] [Related]
3. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
Zhao W; Wu J; Chen S; Zhou Z
Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
5. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
6. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
Bethune MT; Joglekar AV
Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
[TBL] [Abstract][Full Text] [Related]
7. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
8. Tumor neoantigens: from basic research to clinical applications.
Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
[TBL] [Abstract][Full Text] [Related]
9. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
10. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
11. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
Front Immunol; 2021; 12():672356. PubMed ID: 33936118
[TBL] [Abstract][Full Text] [Related]
12. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
13. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
14. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Wirth TC; Kühnel F
Front Immunol; 2017; 8():1848. PubMed ID: 29312332
[TBL] [Abstract][Full Text] [Related]
16. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatic methods for cancer neoantigen prediction.
Boegel S; Castle JC; Kodysh J; O'Donnell T; Rubinsteyn A
Prog Mol Biol Transl Sci; 2019; 164():25-60. PubMed ID: 31383407
[TBL] [Abstract][Full Text] [Related]
18. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
19. Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A; Snyder A; Chan TA
Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
[TBL] [Abstract][Full Text] [Related]
20. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
